Table 4.

Analysis of variables influencing the probability of DFS at 5 years

Variable	Value	N	Events	DFS (%)	P value
Gender	Male	69	35	47 ± 6	.16
	Female	41	26	35 ± 8
Age at diagnosis	<1.4 y	51	23	53 ± 7	.012
	>1.4 y	52	35	30 ± 7
Patient HCMV status	Negative	49	26	44 ± 8	.47
	Positive	61	35	42 ± 7
Interval diagnosis-UCBT	<5.6 mo	55	31	43 ± 7	.52
	>5.6 mo	55	30	43 ± 7
Cytogenetics at diagnosis	Missing	36	16	54 ± 9	.073
	Normal	44	24	45 ± 8
	Other/abnormal	11	6	40 ± 16
	Monosomy 7	19	15	21 ± 9
WBC at diagnosis	<35 × 109/L	49	26	47 ± 7	.8
	>35 × 109/L	49	28	39 ± 7
HbF at diagnosis	<13%	29	17	42 ± 10	.93
	>13%	31	17	43 ± 9
PLT at diagnosis	<42.5 × 109/L	46	29	37 ± 7	.12
	>42.5 × 109/L	46	23	46 ± 8
Pre-HSCT treatment	No or low dose	68	43	36 ± 6	.12
	AML-like	34	16	55 ± 9
Splenectomy	No	74	46	36 ± 6	.098
	Yes	28	12	56 ± 10
WBC at UCBT	<11.35 × 109/L	39	21	44 ± 8	.49
	>11.35 × 109/L	39	27	33 ± 8
BM blasts at UCBT	<6%	40	21	44 ± 8	.75
	>6%	40	23	39 ± 8
Year of UCBT	<2003	55	34	38 ± 7	.43
	>2003	55	27	49 ± 7
ABO match	Match	48	28	39 ± 7	.79
	Minor	26	13	53 ± 10
	Major	33	19	38 ± 9
HLA mismatch	0/1 disparity	65	33	48 ± 6	.07
	2-3 disparities	39	27	34 ± 8
TBI during the preparative regimen	No	89	51	41 ± 6	.36
	Yes	21	10	50 ± 11
Conditioning regimens	Others	15	7	53 ± 13	.63
	Bu+Cy+ Mel	47	28	40 ± 8
	TBI+Cy+ other	19	9	51 ± 12
	Bu+Cy+ other	21	12	40 ± 11
MTX in GVHD prophylaxis	No	97	54	43 ± 5	.75
	Yes	12	6	44 ± 16
GVHD prophylaxis	Other	12	7	38 ± 15	.97
	CsA+prednisone	87	48	44 ± 6
	MMF+other	10	5	39 ± 20
Serotherapy	No	15	7	50 ± 14	.34
	Yes	94	54	39 ± 5
TNC infused	<7.1 × 107/kg	52	32	37 ± 7	.18
	>7.1 × 107/kg	57	28	49 ± 7

Bu, busulphan; Cs-A, cyclosporine-A; Cy, cyclophosphamide; Mel, melphalan; MMF, mofetil mycophenolate; MTX, methotrexate; PLT, platelet count; TNC, total nucleated cells.